Roche Granted First FDA Approval For Liquid Biopsy Test Detecting Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Swiss pharmaceutical and biotech firm Roche approval for a "liquid biopsy," or blood-based genetic test, that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) patients, the most common type of lung cancer. It's the first time FDA has approved a liquid biopsy companion diagnostic to aid clinicians in decision-making.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news